Are Analysts Bullish about Avinger Inc (NASDAQ:AVGR) after last week?

November 14, 2017 - By Stephen Andrade

 Are Analysts Bullish about Avinger Inc (NASDAQ:AVGR) after last week?

Avinger Inc (NASDAQ:AVGR) Ratings Coverage

Among 3 analysts covering Avinger (NASDAQ:AVGR), 0 have Buy rating, 0 Sell and 3 Hold. Therefore 0 are positive. Avinger had 3 analyst reports since December 29, 2015 according to SRatingsIntel. The stock of Avinger Inc (NASDAQ:AVGR) has “Perform” rating given on Wednesday, April 12 by Oppenheimer. The firm has “Hold” rating given on Tuesday, April 11 by Canaccord Genuity. The firm has “Neutral” rating given on Tuesday, December 29 by Dougherty & Company. Below is a list of Avinger Inc (NASDAQ:AVGR) latest ratings and price target changes.

About 815,070 shares traded. Avinger Inc (NASDAQ:AVGR) has declined 96.51% since November 14, 2016 and is downtrending. It has underperformed by 113.21% the S&P500.

Avinger, Inc. is a commercial-stage medical device company. The company has market cap of $6.14 million. The Firm designs, makes and sells image-guided, catheter systems that are used by physicians to treat patients with peripheral arterial disease . It currently has negative earnings. The Firm focuses on introducing products based on its lumivascular platform, which is an intravascular image-guided system.

More important recent Avinger Inc (NASDAQ:AVGR) news were published by: which released: “Avinger to Announce Third Quarter 2017 Results on November 9, 2017” on October 31, 2017, also published article titled: “Avinger Receives 510(k) Clearance for Design Modifications to Enhance …”, published: “Avinger Announces First Patient Enrolled in its IDE Study of the Pantheris …” on October 19, 2017. More interesting news about Avinger Inc (NASDAQ:AVGR) was released by: and their article: “Avinger Announces Third Quarter 2017 Results” with publication date: November 09, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.